OC
ACHN

Oppenheimer & Co’s Achillion Pharmaceuticals ACHN Stock Holding History

Oppenheimer & Co’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-83,045
Closed -$251K – 1472
2013
Q3 		$251K Buy
+83,045
New +$569K 0.01% 1055

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Oppenheimer & Co's ACHN Position: Q4 2013 in Review

Oppenheimer & Co sold out of Achillion Pharmaceuticals (ACHN) in Q4 2013, closing a stake of 83,045 shares — an estimated $251K sold.

Oppenheimer & Co first reported a position in ACHN in Q3 2013 and held it in 1 quarter. The position peaked at $251K in Q3 2013. 93 funds tracked by Wall St. Rank hold ACHN as of Q4 2013.

  • Oppenheimer & Co reported no remaining Achillion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 83,045 Achillion Pharmaceuticals shares in Q4 2013, an estimated $251K.
  • Oppenheimer & Co first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Oppenheimer & Co's Achillion Pharmaceuticals position peaked at $251K in Q3 2013.
  • 93 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2013.

Based on Oppenheimer & Co's 13F filing for Q4 2013, filed 12 Feb 2014.